Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729846 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
A Phase 2 study, sponsored by California Retina Consultants.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00729846: Completed Phase 2 study, sponsored by California Retina Consultants.
NCT00729846 is a Phase 2 study that has completed, run by California Retina Consultants. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00729846, a Phase 2 study, has completed, sponsored by California Retina Consultants.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.
Interventions
- DRUG Bevacizumab
- DEVICE verteporfin photodynamic therapy reduced fluence
- DEVICE verteporfin photodynamic therapy standardfluence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00729846 record still lists
NCT00729846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00729846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00729846 about?
NCT00729846 is a clinical study titled "Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)". To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degenerat...
What is the current status of trial NCT00729846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00729846?
The interventions under investigation include: Bevacizumab (DRUG), verteporfin photodynamic therapy reduced fluence (DEVICE), verteporfin photodynamic therapy standardfluence (DEVICE).
Who is sponsoring clinical trial NCT00729846?
This trial is sponsored by California Retina Consultants, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00729846's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia